On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed Martin Olin as the Chairman of the Board. Martin Olin is CEO of BerGenBio and has been on the Board of Cessatech since August 2020. His biotech experience and knowledge of the company will be important as Cessatech moves into the next development for CT001. The previous Chairman of the Board, Adam Steensberg will continue as Board member of Cessatech. Martin Olin will be allocated additional 20,000 incentive warrants (in total 65,000) to the same level as previously allocated to the Chairman of the Board from the January 2023 allocation. Incentive warrant terms are the same as previously announced 17 January 2023

Comment from Martin Olin, Chairman of the Board of Directors, Cessatech
Since joining the Board of Directors, I have been truly impressed with the scientific rigor, quality and speed with which the company operates and look forward working with the Board, Jes Trygved and the team to progress our mission of bringing innovative new medicines to children.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.